Cryopreserved Platelets (CPP) for US FDA Licensure

The Defense Health Agency (DHA) is issuing a Sources‑Sought notice (HT9427‑26‑RFI‑705) to identify commercial partners capable of developing, licensing, and managing a dimethyl‑sulfoxide (DMSO) cryopreserved platelet (CPP) product for U.S. military use. The CPP is a frozen, biologic‑platelet formulation designed to extend shelf life to two years or longer—significantly beyond the 5‑7‑day limit of current liquid‑stored platelets—thereby enhancing readiness and survivability of the warfighter. DHA seeks expertise in product development, FDA licensure, and long‑term supply chain management of this novel blood component. Responses are due by 15:00 EST on 4 May 2026. Point of contact is Peter Mitchell (peter.d.mitchell8.civ@health.mil). Work will be performed at the DHA location in Frederick, Maryland (21702). NAICS code 541715 (Research and Development in the Physical, Engineering, and Life Sciences) applies. Interested firms should submit capability statements outlining experience with biologic product development, cryopreservation, regulatory approval, and large‑scale manufacturing.

Notice ID

6af44860d1524f628c0124e06e4bb8b6

Solicitation Number

HT9427-26-RFI-705

NAICS Code

541715

Classification Code

N/A